Elizabeth S. Klings, MD
Adjunct Assistant Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, New York University School of Medicine




Dr. Klings is an Associate Professor in the Department of Medicine. She is the Director of the Center for Excellence in Sickle Cell Disease and the Director of the Pulmonary Hypertension at BUSM/Boston Medical Center. She has an outpatient clinical practice focused on patients with pulmonary hypertension and those with pulmonary complications of sickle cell disease. She attends in the Medical Intensive Care Unit and on the Pulmonary Hypertension Consultation Service at Boston Medical Center. As Director of the largest sickle cell center in New England, Dr. Klings has created numerous new clinical programs for our patients and has expanded the clinical trials program.

Dr. Klings’ research since fellowship has focused on pathogenesis of pulmonary vascular complications of sickle cell disease. She is an NIH-funded Principal Investigator .in the Pulmonary Center collaborating with numerous other investigators across the medical campus. She has phenotypically screened over 200 sickle cell patients at Boston Medical Center for the presence of pulmonary hypertension and currently investigating the roles of disease modulators including sleep-disordered breathing and venous thromboembolism in the endothelial and vascular dysfunction these patients experience. Known internationally as a leader in the care and treatment of patients with sickle cell disease, she was first author of the American Thoracic Society sponsored clinical guidelines for Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease. She recently chaired an ATS sponsored workshop to define clinical and research priorities in sickle cell lung disease and serves on the NHLBI Sickle Cell Disease Advisory Committee.

Diversity, Equity, Inclusion and Accessibility

My commitment to diversity, equity and inclusion dates back to medical school. I came to BU for Internal Medicine Residency training at the then Boston City Hospital to work specifically with an underserved population and was excited by resources that existed here over 20 years ago to improve the healthcare of these patients. During my pulmonary/critical care fellowship, I began to study the pulmonary vascular complications of sickle cell disease. As I joined the faculty in 2000, I began to understand that my work in sickle cell disease coupled exciting science with a population riddled by profound healthcare disparities. I have remained committed to this work since that time. As Director of the Center for Excellence in Sickle Cell Disease, I oversee a diverse group of physicians, advanced practice providers, social workers, patient navigators and research staff dedicated to improving care for our patients.

One of my passions is mentoring trainees and junior faculty, particularly in research. I have over 30 prior and current research mentees, many of whom identify as female or members of under-represented groups. As a member of the LGBTQ+ community, I understand the importance of not only recruiting a diverse group of trainees but assisting them in overcoming barriers to their development.

Within the Pulmonary Center, I serve in two important, and partiaily overlapping, roles. I am the co-chair of our Diversity and Inclusion Faculty Recruitment Committee which has as its goal the identification and recruitment of diverse faculty candidates. Since 2021, I have been the chair of our Racial Equity committee which is leading our division's monthly education sessions on topics of race, health equity, career development and related issues.

Member
Boston University
Pulmonary Center


Program Director
Boston University
Center of Excellence in Sickle Cell Disease


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




Protocol 21427/BAY0903201: ROAR: Riociguat Users Registry
07/13/2021 - 02/28/2024 (PI)
Bayer HealthCare Pharmaceuticals


Protocol # STERIO-SCD, A Phase lib Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases
03/20/2018 - 09/19/2023 (Subcontract PI)
University of Pittsburgh Bayer HealthCare


Protocol # 402-C-1602, An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension.
07/27/2017 - 07/26/2022 (PI)
Reata Pharmaceuticals, Inc.


Protocol #APD811-303: A Study Evaluating the Long-Term Efficacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
02/06/2019 - 02/06/2022 (PI)
United Therapeutics Corporation


Assessing the effectiveness of anti-sickling agents for sickle hemoglobin and red blood cells
02/01/2016 - 01/31/2022 (PI)
The General Hospital Corporation d/b/a Massachusetts General Hospital


An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension
12/12/2014 - 12/31/2021 (PI)
Arena Pharmaceuticals Inc.


A StuDy eVAluatiNg the EfficaCy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
11/30/2018 - 11/30/2021 (PI)
United Therapeutics Corporation


A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
10/12/2016 - 10/11/2021 (PI)
Reata Pharmaceuticals, Inc.


The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo
07/15/2015 - 07/14/2021 (PI)
Actelion Pharmaceuticals, Ltd.


Neutrophil Elastase as a Biomarker for Neutrophil-mediated Pathbiology in Sickle Cell Disease
12/21/2015 - 06/20/2021 (Subcontract PI)
Children's Hospital, Oakland Bayer HealthCare


Showing 10 of 31 results. Show All Results

SEG101 (STAND): A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and …
01/23/2020 - 03/01/2028 (PI)
Novartis Pharma Corp

SCD-CARRE 1/2 Sickle Cell Disease and CardiovAscul_Copy
05/01/2020 - 04/30/2026 (PI)
University of Pittsburgh National Heart, Lung

4202-HEM-301: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE).
03/24/2021 - 03/23/2024 (PI)
Forma Therapeutics, Inc.


Title


Yr Title Project-Sub Proj Pubs
2013 Protein biomarkers of pulmonary hypertension in sickle cell disease 5R21HL107993-02 3
2012 Protein biomarkers of pulmonary hypertension in sickle cell disease 1R21HL107993-01A1 3
2011 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-15-5116 259
2010 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-14-6816 259
2009 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-13-6167 259
2009 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-05 7
2008 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-12-5241 259
2008 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-04 7
2007 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 2P41RR010888-11-8062 259
2007 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-03 7
Showing 10 of 17 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Johnson SW, Gillmeyer KR, Bolton RE, McCullough MB, Qian SX, Maron BA, Klings ES, Wiener RS. Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy. Ann Am Thorac Soc. 2022 Mar 21.View Related Profiles. PMID: 35312466
     
  2. Klings ES, Steinberg MH. Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management. Expert Rev Hematol. 2022 Feb; 15(2):117-125.View Related Profiles. PMID: 35143368
     
  3. Moy ML, Wayne PM, Litrownik D, Beach D, Klings ES, Davis RB, Pinheiro A, Yeh GY. Long-term Exercise After Pulmonary Rehabilitation (LEAP): a pilot randomised controlled trial of Tai Chi in COPD. ERJ Open Res. 2021 Jul; 7(3).View Related Profiles. PMID: 34262967; PMCID: PMC8273295; DOI: 10.1183/23120541.00025-2021;
     
  4. Belok SH, Bosch NA, Klings ES, Walkey AJ. Evaluation of leukopenia during sepsis as a marker of sepsis-defining organ dysfunction. PLoS One. 2021; 16(6):e0252206.View Related Profiles. PMID: 34166406; PMCID: PMC8224900; DOI: 10.1371/journal.pone.0252206;
     
  5. Kraemer KM, Litrownik D, Moy ML, Wayne PM, Beach D, Klings ES, Reyes Nieva H, Pinheiro A, Davis RB, Yeh GY. Exploring Tai Chi Exercise and Mind-Body Breathing in Patients with COPD in a Randomized Controlled Feasibility Trial. COPD. 2021 06; 18(3):288-298.View Related Profiles. PMID: 34106027; PMCID: PMC8283813; DOI: 10.1080/15412555.2021.1928037;
     
  6. Lui JK, Sangani RA, Chen CA, Bujor AM, Trojanowski MA, Gopal DM, LaValley MP, Soylemez Wiener R, Klings ES. Prognostic Value of Cardiac Axis Deviation in Systemic Sclerosis-Related Pulmonary Hypertension. Arthritis Care Res (Hoboken). 2021 Jun 03.View Related Profiles. PMID: 34085410; PMCID: PMC8639831; DOI: 10.1002/acr.24724;
     
  7. Cramer-Bour C, Ruhl AP, Nouraie SM, Emeh RO, Ruopp NF, Thein SL, Weir NA, Klings ES. Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease. Eur J Haematol. 2021 Jul; 107(1):54-62. PMID: 33650125; PMCID: PMC8730705; DOI: 10.1111/ejh.13612;
     
  8. Cramer-Bour C, Peterson J, Walsh B, Klings ES. Common Complications of Sickle Cell Disease: A Simulation-Based Curriculum. MedEdPORTAL. 2021 04 02; 17:11139. PMID: 33851012; PMCID: PMC8034233; DOI: 10.15766/mep_2374-8265.11139;
     
  9. Gillmeyer KR, Miller DR, Glickman ME, Qian SX, Klings ES, Maron BA, Hanlon JT, Rinne ST, Wiener RS. Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease. Pulm Circ. 2021 Apr-Jun; 11(2):20458940211001714.View Related Profiles. PMID: 33868640; PMCID: PMC8020250; DOI: 10.1177/20458940211001714;
     
  10. Lui JK, Mesfin N, Tugal D, Klings ES, Govender P, Berman JS. Critical Care of Patients With Cardiopulmonary Complications of Sarcoidosis. J Intensive Care Med. 2022 Apr; 37(4):441-458.View Related Profiles. PMID: 33611981
     
Showing 10 of 76 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 76 publications over 24 distinct years, with a maximum of 9 publications in 2021

YearPublications
19992
20003
20014
20022
20031
20041
20052
20062
20072
20082
20093
20102
20113
20123
20131
20146
20154
20162
20173
20185
20195
20207
20219
20222
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

anemia, sickle cell
endothelium
pulmonary hypertension

Available to Mentor as: (Review Mentor Role Definitions):
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

85 E. Concord St Housman (R)
Boston MA 02118
Google Map


Klings's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department